Clinical Trials Directory

Trials / Unknown

UnknownNCT05174338

Cardiac Amyloidosis Registry Study

Cardiac Amyloidosis Registry Study - A Multi-Center, Longitudinal, Observational Survey of Patients With Cardiac Amyloidosis

Status
Unknown
Phase
Study type
Observational
Enrollment
5,000 (estimated)
Sponsor
Cedars-Sinai Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and internationally between 1997 and 2025.

Detailed description

Amyloidosis is a rare, multisystem disorder in which an insoluble protein is deposited in tissues, leading to organ dysfunction. Several proteins have been identified to potentially lead to amyloid cardiomyopathy (AC). Given the rare nature of these diseases, a large, multi-center effort to describe the characteristics of these patients and their outcomes with novel treatment modalities has not been established. (TBD) academic medical centers from the US and internationally will compile demographic, hemodynamic and organ-involvement data, as well as treatment strategies for AL and TTR amyloidosis. This registry is an observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and internationally between 1997 and 2025. It is expected that the total patient population will be approximately 5000 patients.

Conditions

Interventions

TypeNameDescription
OTHERRegistryObservational, data collection

Timeline

Start date
2020-01-08
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2021-12-30
Last updated
2023-09-06

Locations

23 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT05174338. Inclusion in this directory is not an endorsement.